Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
grade A 39.5642 1.51% 0.59
ARWR closed up 6.78 percent on Tuesday, October 22, 2019, on 1.34 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ARWR trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 1.51%
New 52 Week High Strength 1.51%
Upper Bollinger Band Walk Strength 1.51%
Wide Bands Range Expansion 1.51%
Above Upper BB Strength 1.51%
Overbought Stochastic Strength 1.51%
Upper Bollinger Band Touch Strength 1.51%
180 Bullish Setup Bullish Swing Setup 8.40%
Slingshot Bullish Bullish Swing Setup 8.40%
Upper Bollinger Band Walk Strength 8.40%

Older signals for ARWR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Biology Organ Systems Solid Tumors Infection Molecular Biology Obesity Genetics Gene Expression Hepatitis B RNA Molecular Genetics Apoptosis Biochemistry Chronic Hepatitis B Virus
Is ARWR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 39.25
52 Week Low 10.41
Average Volume 1,373,043
200-Day Moving Average 23.7844
50-Day Moving Average 31.4554
20-Day Moving Average 31.8565
10-Day Moving Average 34.564
Average True Range 1.725
ADX 32.86
+DI 42.3644
-DI 9.1342
Chandelier Exit (Long, 3 ATRs ) 34.075
Chandelier Exit (Short, 3 ATRs ) 31.145
Upper Bollinger Band 38.5911
Lower Bollinger Band 25.1219
Percent B (%b) 1.03
BandWidth 42.280853
MACD Line 1.8954
MACD Signal Line 1.0968
MACD Histogram 0.7987
Fundamentals Value
Market Cap 2.91 Billion
Num Shares 74.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -60.90
Price-to-Sales 11.15
Price-to-Book 2.81
PEG Ratio -1.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.53
Resistance 3 (R3) 42.23 40.74 41.94
Resistance 2 (R2) 40.74 39.83 40.89 41.74
Resistance 1 (R1) 39.86 39.27 40.30 40.16 41.54
Pivot Point 38.37 38.37 38.59 38.52 38.37
Support 1 (S1) 37.49 37.46 37.93 37.79 36.41
Support 2 (S2) 36.00 36.90 36.15 36.21
Support 3 (S3) 35.12 36.00 36.01
Support 4 (S4) 35.42